New Technology– category –
-
Qihan Biotech’s Universal Dual-Target Hypoimmune CAR-T Therapy QT-019B Receives FDA RMAT and Breakthrough Therapy Designations
PackGene Biotech China Overview Qihan Biotech's universal dual-target CAR-T therapy, QT-019B, has received both FDA Regenerative Medicine Advanced Therapy (RMAT) and Breakthrough Therapy Designations (BTD). This off-the-shelf allogeneic ... -
University of Houston Researchers Discover Salt Significantly Enhances Lipid Nanoparticle Delivery Efficiency in Gene Therapy
University of Houston USA Overview University of Houston researchers have discovered that adding salt to lipid nanoparticles (LNPs) dramatically improves the intracellular delivery efficiency of mRNA vaccines and gene therapeutics. This ... -
FDA Unleashes Real-Time Clinical Trials: An AI-Driven Revolution for Faster Drug Development
ICON plc アイルランド Overview The U.S. FDA has launched its Real-time Clinical Trials (RTCT) initiative, a pivotal program designed to dramatically accelerate drug development. By enabling near real-time data sharing with regulators and... -
UT MD Anderson Develops Exosome-Based Therapy for Duchenne Muscular Dystrophy, Delivering Full-Length DMD mRNA to Dramatically Restore Muscle Function In Vivo
Nature Biomedical Engineering (via The University of Texas MD Anderson Cancer Center) USA Overview Researchers at The University of Texas MD Anderson Cancer Center have developed a novel therapeutic platform utilizing engineered extracel... -
Broad Institute Achieves Major Breakthrough in Prime Editing: Enhanced In Vivo Delivery with Optimized LNPs Paves Way for Broader Genetic Disease Therapies
Broad Institute USA Overview Researchers at the Broad Institute have significantly improved the efficiency and specificity of prime editing by optimizing its core components and developing an advanced lipid nanoparticle (LNP) delivery sy... -
uniQure Announces Plan for BLA Submission of Huntington’s Disease Gene Therapy AMT-130, FDA Accepts Phase 1/2 3-Year Data for Accelerated Approval
uniQure Press Release USA Overview uniQure has announced that the FDA agreed in a Type B meeting that 3-year analysis data from its Phase 1/2 trial of gene therapy AMT-130 for Huntington's Disease (HD) would be acceptable as primary evid... -
FDA Grants RMAT Designation to Cellectis’ Allogeneic CD22 CAR-T Lasme-cel for Relapsed/Refractory B-ALL
Targeted Oncology USA Overview The FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to Cellectis' lasmecabtagene timgedleucel (lasme-cel; UCART22), an allogeneic CD22-targeting CAR-T cell therapy, for relapsed/re... -
Multimodal AI in 2026: GPT-4o Highlights Real-time Voice with Emotion, Integrating Text, Image, Audio, and Video as Standard for Frontier Models
explainx.ai International Overview This guide explains multimodal AI models, which can process and produce various data types—text, images, audio, and video—within a unified system, unlike traditional unimodal models. The key architectur... -
NVIDIA Maintains 80% AI Chip Market Dominance via CUDA, But Google TPU, AMD, and Custom Silicon Intensify Competition
WEEX Crypto Wiki International Overview NVIDIA commands approximately 80% of the AI accelerator market, largely due to its CUDA software ecosystem, despite increasing competition. Google's TPU v5 chips are emerging as a cost-effective al... -
Liquid Cooling Becomes Imperative for AI Data Centers: Addressing 100kW+ Rack Densities, Enhancing Efficiency, and Supporting Next-Gen Hardware
MEP Academy International Overview Liquid cooling is emerging as a critical technology for AI data centers as modern AI servers, equipped with multiple GPUs, push rack densities beyond 100 kW. Traditional air cooling reaches its limits a...
